Compare IPHA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPHA | ACOG |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | France | Canada |
| Employees | 163 | 57 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.4M | 110.4M |
| IPO Year | N/A | N/A |
| Metric | IPHA | ACOG |
|---|---|---|
| Price | $1.46 | $6.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.75 | ★ $16.00 |
| AVG Volume (30 Days) | 23.2K | ★ 38.5K |
| Earning Date | 03-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $180.36 | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $4.50 |
| 52 Week High | $2.63 | $10.88 |
| Indicator | IPHA | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 46.61 |
| Support Level | $1.35 | $5.00 |
| Resistance Level | $1.80 | $6.59 |
| Average True Range (ATR) | 0.08 | 0.42 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 50.00 | 28.62 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.